 Connection
Marco Del Chiaro to Recombinant Fusion Proteins
This is a "connection" page, showing publications Marco Del Chiaro has written about Recombinant Fusion Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.149 |
|
|
|
-
Boggi U, Vistoli F, Signori S, Del Chiaro M, Amorese G, Barsotti M, Rizzo G, Marchetti P, Danesi R, Del Tacca M, Mosca F. Efficacy and safety of basiliximab in kidney transplantation. Expert Opin Drug Saf. 2005 May; 4(3):473-90.
Score: 0.050
-
Boggi U, Danesi R, Vistoli F, Del Chiaro M, Signori S, Marchetti P, Del Tacca M, Mosca F. A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf. 2004; 27(2):91-106.
Score: 0.046
-
Boggi U, Vistoli F, Del Chiaro M, Bartolo TV, Rizzo G, Mosca F. CSA/MMF/steroids versus CSA/AZA/steroids with and without basiliximab in cadaveric kidney transplantation. Transplant Proc. 2001 Nov-Dec; 33(7-8):3199-200.
Score: 0.040
-
Boggi U, Vistoli F, Del Chiaro M, Signori S, Amorese G, Vahadia Bartolo T, Sgambelluri F, Barsotti M, Tregnaghi C, Paleologo G, Coppelli A, Giannarelli R, Rizzo G, Marchetti P, Mosca F. Neoral versus prograf in simultaneous pancreas-kidney transplantation with portal venous drainage: three-year results of a single-center, open-label, prospective, randomized pilot study. Transplant Proc. 2005 Jul-Aug; 37(6):2641-3.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|